683 Capital Management’s Mereo BioPharma MREO Stock Holding History

683 Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.96M	Sell	12,000,000 -3,025,000	-20%	-$1.3M	0.21%	84
2025 Q4	$6.26M	Buy	15,025,000 +10,150,000	+208%	+$19.3M	0.27%	69
2025 Q3	$10M	Buy	4,875,000 +525,000	+12%	+$968K	0.52%	46
2025 Q2	$11.8M	Sell	4,350,000 -285,000	-6%	-$688K	0.77%	34
2025 Q1	$10.4M	Buy	4,635,000 +85,000	+2%	+$240K	0.72%	40
2024 Q4	$15.9M	Sell	4,550,000 -299,800	-6%	-$1.18M	0.99%	22
2024 Q3	$19.9M	Sell	4,849,800 -150,200	-3%	-$621K	1.52%	16
2024 Q2	$18M	Sell	5,000,000 -750,000	-13%	-$2.43M	1.36%	20
2024 Q1	$19M	Sell	5,750,000 -450,000	-7%	-$1.52M	1.39%	20
2023 Q4	$14.3M	Buy	6,200,000 +200,000	+3%	+$383K	1.17%	30
2023 Q3	$7.74M	Buy	6,000,000 +600,000	+11%	+$796K	0.6%	54
2023 Q2	$7.13M	Buy	5,400,000 +3,400,000	+170%	+$3.94M	0.51%	55
2023 Q1	$1.41M	Buy	2,000,000 +1,875,000	+1,500%	+$1.69M	0.11%	131
2022 Q4	$93.8K	Buy	+125,000	New	+$103K	0.01%	237

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

683 Capital Management's MREO Position: Q1 2026 in Review

683 Capital Management reduced its Mereo BioPharma (MREO) stake by 20% in Q1 2026, selling an estimated $1.3M and leaving 12,000,000 shares worth $3.96M. The position accounts for 0.21% of the portfolio, ranked #84.

683 Capital Management first reported a position in MREO in Q4 2022 and has held it in 14 quarters since. The position peaked at $19.9M in Q3 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

683 Capital Management held 12,000,000 shares of Mereo BioPharma worth $3.96M as of Q1 2026.
683 Capital Management sold 3,025,000 Mereo BioPharma shares in Q1 2026, an estimated $1.3M.
Mereo BioPharma made up 0.21% of 683 Capital Management's portfolio in Q1 2026, its #84 holding.
683 Capital Management first reported a position in Mereo BioPharma in Q4 2022 and has held it in 14 quarters since.
683 Capital Management's Mereo BioPharma position peaked at $19.9M in Q3 2024.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.